Traditional Chinese medicine composition for treating esophageal cancer as well as preparation method and application of traditional Chinese medicine composition

Abstract

The invention provides a traditional Chinese medicine composition for treating esophageal cancer, the traditional Chinese medicine composition is prepared from the following medicines in parts by weight: 10-20 parts of codonopsis pilosula, 10-20 parts of garden balsam seed, 6-10 parts of gecko, 20-40 parts of salvia chinensis, 10-20 parts of prepared arisaema consanguineum schott, 10-20 parts of roasted fructus chebulae and 10-20 parts of trifoliate orange, the invention discloses a preparation method of the traditional Chinese medicine composition, and also discloses application of the traditional Chinese medicine composition and an anti-tumor medicine in preparation of a medicine for treating esophageal cancer. The traditional Chinese medicine composition is reasonable in formula principle and remarkable in effect, and has good clinical application value and social significance.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a Chinese medicine composition for treating esophageal cancer, and a preparation method and application thereof. Background Art

[0002] Esophageal cancer (ESCA) is a common malignant tumor of the digestive system, which is usually divided into esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). At present, factors such as obesity, irregular diet, and disordered life rhythm lead to high morbidity and mortality of ESCA, and it is increasing year by year. In addition, characteristics such as high invasiveness, easy metastasis, and poor prognosis are the root causes of the high mortality rate of ESCA patients. At present, the clinical treatment strategies for ESCA are usually mainly surgical resection, chemotherapy, radiotherapy, etc. However, the current clinical treatment methods for esophageal cancer have always had serious sequelae, such as postoperative infection, high cytotoxicity and limited therapeutic effects, resulting in a very poor prognosis and a very low overall five-year survival rate of patients.

[0003] As a traditional method for treating diseases, Chinese medicine has a history of thousands of years and has saved countless lives. The ingredients of Chinese medicine mainly come from nature, such as plants, insects, and refined minerals, and then Chinese medicine formulas are continuously configured to treat diseases. Therefore, seeking a universal and effective method to treat esophageal cancer is a technical problem that needs to be solved in this field. Summary of the invention

[0004] In order to overcome the defects of the prior art, the present invention aims to provide a Chinese medicine composition for treating esophageal cancer and a preparation method and application thereof.

[0005] The present invention is achieved through the following technical solutions:

[0006] The first aspect of the present invention provides a Chinese medicine composition for treating esophageal cancer, which is prepared from the following drugs in parts by weight: 10-20 parts of processed Arisaema confusa, 20-40 parts of Lithospermum officinale, 10-20 parts of Aconitum carmichaelii, 6-10 parts of Gekko, 10-20 parts of Codonopsis pilosula, 10-20 parts of Stewed Terminalia chebula, and 10-20 parts of Citrus aurantium;

[0007] Furthermore, the Chinese medicine composition for treating esophageal cancer is prepared from the following drugs in parts by weight: 15 parts of processed Arisaema, 30 parts of Lithospermum officinale, 15 parts of Codonopsis pilosula, 15 parts of Aconitum carmichaelii, 9 parts of Gekko, 15 parts of stewed Terminalia chebula, and 15 parts of Citrus aurantium;

[0008] The second aspect of the present invention provides a method for preparing any one of the above-mentioned Chinese medicine compositions for treating esophageal cancer, comprising the following steps:

[0009] Take each drug according to the above weight ratio, add water 10 to 20 times the total weight of the drugs, soak for 20 to 60 minutes, then heat and boil for 30 minutes to 2 hours, then filter, freeze-dry the filtrate, collect the yellow powder and store it at 4 to 10°C to obtain;

[0010] The third aspect of the present invention provides a medicine for treating esophageal cancer, comprising any one of the above-mentioned Chinese medicine compositions and a pharmaceutically acceptable carrier;

[0011] Furthermore, the drug for treating esophageal cancer is an oral preparation;

[0012] The fourth aspect of the present invention provides the use of any one of the above-mentioned Chinese medicine compositions in the preparation of a drug for treating esophageal cancer;

[0013] Furthermore, the use is combined with anti-tumor drugs;

[0014] Furthermore, the anti-tumor drug is selected from anti-EGFR drugs; further, the anti-EGFR drug is selected from any one or more of gefitinib, osimertinib, icotinib, erlotinib, and afatinib.

[0015] Furthermore, the treatment of esophageal cancer has the effect of inhibiting tumor growth and prolonging patient survival; BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 Description of the mechanism of action of the esophageal tonifying prescription of the present invention in treating ESCA

[0017] Figure 2 Positive Cav-1 signal in esophageal cancer tissue and adjacent tissue of the present invention

[0018] Figure 3 Analysis of the apoptosis mechanism of the composition of the present invention in ESCA

[0019] Figure 4 The composition of the invention has concentration- and time-dependent cytotoxicity

[0020] Figure 5 The therapeutic effect of the formula composition of the present invention combined with gefitinib

[0021] Beneficial Effects

[0022] The present invention adopts the following medicine preparation:

[0023] Processed Arisaema: Processed Arisaema (Rhizoma arisaematis) is Yunanxing, also known as Huianxing and Yuzhou Arisaema. It is produced in Henan and distributed in Yuzhou. It has the best quality and is sold throughout the country and exported. The surface of processed Arisaema is off-white or light brown, relatively smooth, with a sunken stem scar on the top and pockmarked root scars around it. Some tubers have small flat spherical lateral buds around them. It is hard and not easy to break. The cross section is uneven, white, and powdery. It has a slightly spicy smell and a spicy taste. Arisaema (botanical name: Arisaema heterophyllum Blume) is a general name for Arisaema from all over the country. It is best to have large, uniform, skinless, white, and powdery ones. It is a herbaceous plant belonging to the Araceae family. The Araceae family belongs to the genus Araceae, and its medicinal part is its tuber. The peduncle is shorter than the petiole, the spathe is green and purple, sometimes with white stripes; the spadix is ​​unisexual, dioecious; the female inflorescence has a rod-shaped appendage with many neutral flowers below; there is no perianth, and the ovary is ovate; the appendage of the male inflorescence is smooth below and has a few neutral flowers; there is no perianth, and the stamens are 2-4. The berry is red and spherical.

[0024] Shijianchuan, a Chinese medicinal material. This product is the whole herb of the Lamiaceae plant purple ginseng. It is harvested between the summer solstice and the end of summer. Functions and indications: treating dysphagia, phlegm and asthma, hepatitis, leucorrhea, carbuncle, scrofula. ① "Compendium of Materia Medica": treating bone pain, gale, carbuncle. ② "Suzhou Native Medicinal Materials": treating dysphagia, phlegm and asthma. ③ "Jiangsu Medicinal Materials": treating scrofula. ① For the treatment of acute and chronic hepatitis, take 2 liang of purple ginseng, or add 1 liang of glutinous rice straw, decoct twice in water, combine the decoction and add half a liang of brown sugar, and take it twice (half for children). ② For the treatment of leucorrhea, take 2 liang of Shidachuan, decoct in water. The whole herb contains sterols, triterpenoid components, and amino acids. The root contains stachyose.

[0025] Codonopsis pilosula (Franch.) Nannf., a perennial herbaceous vine of the Campanulaceae family. The root of Codonopsis pilosula is conical, with a grayish-yellow surface and ring patterns. The head of the root has raised stem scars and buds, commonly known as "lion's head", and branches begin to appear from the middle; the rhizomes are smooth, numerous, and all intertwined; the lower end of the leaves is heart-shaped, with serrated edges; the flowers are light yellow-green with dirty purple spots; the lower part of the fruit is hemispherical, the upper part is short conical, and the flowering period is July-August, and the fruiting period is August-September. The name of Codonopsis pilosula was first seen in the Qing Dynasty's "Compendium of Materia Medica Congxin". Codonopsis pilosula was first recorded as a medicine in the Qing Dynasty's "Compendium of Materia Medica Congxin". Codonopsis pilosula is sweet and flat in nature; it enters the spleen and lung meridians; it has the effects of strengthening the spleen and lungs, nourishing blood and promoting body fluid. Modern pharmacological research shows that Codonopsis also has a variety of pharmacological effects, such as enhancing immunity, protecting gastrointestinal mucosa and anti-ulcer, promoting hematopoietic function, regulating blood sugar, delaying aging, etc. At the same time, Codonopsis is also a health product and can be included in diet. Codonopsis can be made into tea or wine. It can be brewed with perilla in boiling water to make Codonopsis perilla tea, which is used for colds; adding Codonopsis to white wine makes Codonopsis wine.

[0026] Jijizi, a Chinese medicine name. It is the dried mature seeds of Impatiens balsamina L., a plant of the Impatiens family. The fruits are harvested in summer and autumn when they are about to mature, dried in the sun, and the peel and impurities are removed. Nature and flavor: slightly bitter and pungent, warm in nature. Meridians: Lung and liver meridians. Efficacy: blood-breaking, softening, and eliminating accumulation. Indications: Used for lumps and masses, amenorrhea, and dysphagia.

[0027] Geckos are reptiles of the genus Gekko of the family Gekkonidae. They are relatively flat, with an adult length of 10 to 15 cm, and the tail is roughly the same length as the head. The back is often light gray-brown, with several irregular brown horizontal stripes on the back of the body, and brown horizontal stripes on the back of the limbs and the back of the tail. The color of the stripes varies greatly, and some individuals have lighter color stripes. The back of the body is covered with granular scales. Because they live on walls and are good at catching scorpions and flies, they are called geckos. Geckos are distributed in Guangxi, Guangdong, Fujian, Yunnan and other places in China; they like to live in secluded places such as between walls and under eaves, and appear on ceilings and walls at night to prey on mosquitoes, flies and other insects. Geckos reproduce by laying eggs, and the breeding season is from June to July. Two eggs are laid each time, which are oval, white, and have thin and hard shells. They stick together and attach to the cracks in the wall. The incubation period is about 2 months, and the young lizard has horn teeth on the tip of its snout. It pecks through the eggshell and comes out. It falls off by itself immediately, and sexual maturity is 2 years old. The medicinal value of gecko is very high. It can cure convulsions, epilepsy, scrofula, tuberculosis, swelling and poison, etc. Its dried product is called "Tianlong". In the "Compendium of Materia Medica" written by Li Shizhen in the Ming Dynasty, gecko is called "Xianchan". It has the effects of relieving cough and asthma, calming spasms and expelling wind, nourishing the liver and kidney, replenishing essence and blood, and dispersing and reducing swelling. The medicinal part of gecko is to use the whole dried body. It is caught in summer and autumn, thrown to death or scalded to death with boiling water, dried in the sun or baked for use. It is cold in nature, salty in taste, and has the effects of relieving pain and dispersing knots.

[0028] Stewed Terminalia chebula: Terminalia chebula, also known as Terminalia chebula, Terminalia chebula, Terminalia chebula, and Terminalia chebula. Source: The fruit of Terminalia chebula or Terminalia chebula of the Combretaceae family. The fruit is picked when it is ripe in late autumn and early winter and dried in the sun. It is distributed in western and southwestern Yunnan, and cultivated in Guangdong and Guangxi. Nature and flavor: bitter, sour, and astringent, warm. Processing: 1. Terminalia chebula meat: Use a hammer to open the Terminalia chebula peel and remove the core. 2. Stir-fried Terminalia chebula: Wash with clean water, dry in the sun, put into the pot and stir-fry with high heat until the surface is dark yellow, take out and cool. Properties: The dried fruit is oval or nearly spherical, 3.5 cm long and 1.5 to 2 cm in diameter. The surface is yellow-green or gray-brown, slightly shiny, with 5 longitudinal ridges and many longitudinal wrinkles, and fine horizontal textures, with a round fruit stalk remnant at the base. The texture is solid, the cross section is gray-yellow, sandy, and gray-brown when it is old. There is a yellow-white hard core inside, which is blunt and round. The shell is thick, and after it is smashed, there is a white and small seed kernel inside. It has a slight smell and tastes sour and astringent. The ones that are yellow-brown, shiny, and firm are preferred. Effects of stewed Terminalia chebula: It is the fruit of Terminalia chebula or Terminalia chebula of the family Combretaceae. It is mainly used to treat long-term cough and aphonia, long-term diarrhea, long-term dysentery, rectal prolapse, blood in the stool, metrorrhagia, leucorrhea, spermatorrhea, and frequent urination. It enters the lung meridian, stomach meridian, and large intestine meridian. Mainly used to astringe the lungs, astringe the intestines, lower the qi, and relieve sore throat. It can treat long-term cough and aphonia, long-term diarrhea, long-term dysentery, rectal prolapse, blood in the stool, metrorrhagia, leucorrhea, spermatorrhea, and frequent urination.

[0029] Poncirus trifoliata: Also known as Tielizhai, Stinky Orange, Poncirus trifoliata, and Stinky Qi, it is derived from the fruit of Poncirustrifoliata (L.) Raf., a plant of the genus Poncirus trifoliata in the Rutaceae family; its leaves are also used for medicinal purposes. Harvest the unripe fruits from July to September, cut into halves or shreds and dry in the shade. Harvest the leaves as needed. Nature and flavor: pungent, bitter, warm. Functions and indications: Fruit: invigorates the stomach and helps digestion, regulates qi and relieves pain. Used for stomachache, indigestion, chest and abdominal distension and pain, constipation, uterine prolapse, rectal prolapse, testicular swelling and pain, and hernia pain. Leaves: promote qi and digestion, and stop vomiting. Used for nausea and vomiting. Usage and dosage: 3 to 5 qian of fruit, up to 1 liang; 2 to 5 qian of leaves.

[0030] The monarch-minister-assistant relationship of the present invention. The Nanxing used in this prescription is an important medicine for treating accumulation and fuliang, which is specifically used to enter the pharynx and diaphragm, and can resolve phlegm and disperse knots; Shijianchuan is good at treating choking, phlegm and asthma, carbuncle, scrofula and other diseases, and takes its bitterness and coldness to control the dryness of Nanxing, and they are all monarch medicines. Tianlong is a commonly used insect medicine for treating cancer, which can enter the blood and attack and disperse the coagulation of qi and blood; Jijizi has the functions of breaking blood stasis and softening hardness, opening and closing the secluded, and Codonopsis pilosula replenishes qi and strengthens the spleen, and strengthens the body to prevent excessive attack, and the three are all minister medicines; to treat phlegm, first treat qi, use Terminalia chebula to break the chest and diaphragm qi, and use it together with Lycium barbarum to reduce qi and eliminate phlegm, digest food and stimulate appetite, and they are all adjuvants. All the medicines are used together, and they have both the function of resolving phlegm, breaking blood stasis, and regulating qi, and the attack and defense complement each other, and they have the effect of opening and closing knots. In addition, the present invention proves through pharmacological experiments that the composition can not only inhibit the expression of Cav-1 at the gene level, but also effectively induce the expression of the anti-apoptotic factor EGFR. In addition, pharmacological experiments have shown that the combination of the present invention's formulation and anti-tumor drugs can significantly inhibit the expression of anti-apoptotic factors EGFR and Cav-1, inhibit the growth of mouse tumors and significantly prolong the survival of mice; the present invention's formulation principle is reasonable, the effect is significant, and it has good clinical application value and social significance. DETAILED DESCRIPTION

[0031] (I) Embodiment

[0032] Example 1

[0033] A traditional Chinese medicine composition for treating esophageal cancer is prepared from the following medicines in parts by weight: 20g of Lithospermum officinale, 10g of processed Arisaema confusa, 10g of Codonopsis pilosula, 10g of Fructus Aconitum, 6g of Gekko, 10g of Stem Terminalia chebula and 10g of Citrus aurantium. Each medicine is taken according to the above weight ratio, water 20 times the total weight of the medicines is added, soaked for 60 minutes, then heated and boiled for 1 hour, filtered, the filtrate is freeze-dried, yellow powder is collected and stored at 4°C to obtain the composition.

[0034] Example 2

[0035] A traditional Chinese medicine composition for treating esophageal cancer is prepared from the following medicines in parts by weight: 40g of Lithospermum officinale, 20g of processed Arisaema confusa, 20g of Codonopsis pilosula, 20g of Fructus Aconiti Lateralis, 10g of Gekko, 20g of Stewed Terminalia chebula, and 20g of Citrus aurantium. Each medicine is taken according to the above weight ratio, and water 20 times the total weight of the medicines is added, soaked for 30 minutes, then heated and boiled for 1 hour, and then filtered. After the filtrate is freeze-dried, yellow powder is collected and stored at 8°C to obtain the composition.

[0036] Example 3

[0037] A traditional Chinese medicine composition for treating esophageal cancer is prepared from the following medicines in parts by weight: 30g of Lithospermum officinale, 15g of processed Arisaema confusa, 15g of Codonopsis pilosula, 15g of Fructus Aconitum, 9g of Gekko, 15g of Stewed Terminalia chebula, and 15g of Citrus aurantium. Each medicine is taken according to the above weight ratio, and water 20 times the total weight of the medicines is added, soaked for 30 minutes, then heated and boiled for 1 hour, and then filtered. After the filtrate is freeze-dried, the yellow powder is collected and stored at 4°C to obtain the composition.

[0038] (II) Experimental Examples

[0039] The experiment was conducted using Example 3 as the administration formula.

[0040] 1. Differences in Cav-1 expression between cancer tissues and adjacent paracancerous tissues.

[0041] Figure 2 Shows: (a) Positive Cav-1 signals in cancerous tissues and paracancerous tissues, with red arrows indicating Cav-1 expression; (b) Overall survival of Cav-1. The difference in Cav-1 expression between cancerous tissues and paracancerous tissues was studied. Immunofluorescence staining showed that there was a significant correlation between the expression of Cav-1 in cancerous tissues and paracancerous tissues (a). Among 101 ESCA patient samples, 42 cases (41.6%) showed high expression of Cav-1 in tumors. In addition, the prognostic value of Cav-1 expression in ESCA was evaluated by univariate analysis of survival based on H cores according to Kaplan-Meier analysis and log-rank test. In ESCA, high expression of Cav-1 predicted poorer survival compared with low expression of Cav-1 (Figure b).

[0042] 2. Analysis of the apoptosis mechanism of Shidaotongjie Recipe (Example 3) in ESCA

[0043] Figure 3 The apoptosis mechanism analysis of Shidao Tongjie Recipe in ESCA is shown. (a) The red nodes are apoptosis factors BCL2, BAX, MCL1, BCL2L1 and BAD, and the yellow nodes are core targets related to apoptosis. (b) GO analysis of the core network. (c) 224 common targets of Shidao Tongjie Recipe and ESCA apoptosis in the STRING database. (d) KEGG analysis.

[0044] Subsequently, a PPI network was generated by loading the cross-targets into the STRING version 11.0 repository and Cytoscape3.8.2 software. Larger and brighter nodes in the PPI network indicate that the associated proteins are more likely to interact with their neighbors. 112 core targets were calculated using the cytoHubba plugin, and 56 factors closely related to apoptosis factors Bcl-2, Bax, MCL1, Bcl-2L1, and BAD were defined as the core network (connections ≤ 4) (Figure a). In addition, in this network, we identified 56 targets closely related to apoptosis, including Cav-1, HSP90AA1, EGFR, JUN, AKT1, etc. (Figure c). In order to better understand the biological pathway mechanism of ESCA treatment mediated by Shidao Tongjie Fang on the basis of overlapping genes, we performed functional enrichment, including GO and KEGG enrichment analysis (Figures b and c). Subsequent functional analysis revealed that the core network was involved in several biological processes, such as apoptotic processes, responses to endogenous stimuli, responses to lipids, regulation of intracellular signal transduction, and hypoxia-inducible factor 1 (HIF-1), phosphoinositide 3-kinase / Akt (PI3K-Akt), JAK-STAT3, and calcium signaling pathways.

[0045] 3. The Shidaotongjie formula has concentration- and time-dependent cytotoxicity

[0046] Figure 4 (a) The cytotoxicity of different concentrations of Shidaotongjie Recipe in TE-1 cells was evaluated by MTT assay after 12 and 24 h of culture. (b) Immunofluorescence of Cav-1 and EGFR in TE-1 cells treated with different samples.

[0047] As shown in the results, the Shidaotongjie recipe of the present invention has concentration- and time-dependent cytotoxicity, effectively killing tumor cells. In addition, TE-1 cells were subjected to immunofluorescence analysis. The collected results found that untreated TE-1 cells showed high expression of Cav-1 (red fluorescence) and low-dose EGFR protein (green fluorescence). However, in the presence of Shidaotongjie recipe, the red signal disappeared appropriately and the green signal increased significantly, indicating that the Shidaotongjie recipe can effectively inhibit the expression of Cav-1, but also stimulate the expression of EGFR. In addition, after culturing EGF in TE-1 cells, EGFR expression was obviously present, while Cav-1 showed insignificant changes. However, in TE-1 cells co-cultured with Shidaotongjie recipe and EGF protein, the red fluorescence was weaker, while the green fluorescence was still obvious. In summary, it is shown that Shidaotongjie recipe can effectively inhibit Cav-1 expression to inhibit tumor cells, but at the same time stimulate the expression of EGFR to inhibit tumor treatment and interfere with the therapeutic effect of Shidaotongjie recipe.

[0048] 4. Therapeutic effect of the combination of the present invention and gefitinib

[0049] Figure 5 This reflects the therapeutic effect of the combination of the composition of the present invention and gefitinib. Figure 5 (a) reflects the tumor images of different mouse groups after treatment with PBS, gefitinib (150 mg / kg), Shidaotongjiefang (200 mg / kg), and Shidaotongjiefang + gefitinib; Figure 5 (b) reflects the results of TUNEL and Ki-67 staining of tumors 30 days after treatment (scale bar, 50 μm). Figure 5 The results showed that after 30 days of treatment, the combination of Shidao Tongjie Recipe and gefitinib showed excellent anti-tumor effects compared with the single treatment groups (Shidao Tongjie Recipe group or gefitinib group). In addition, TUNEL and Ki-67 fluorescent tumor section staining further proved that the combination of Shidao Tongjie Recipe and gefitinib showed effective anti-tumor effects.

[0050] It shows that the pharmaceutical composition of the present invention can effectively inhibit the expression of Cav-1 to inhibit tumor cell apoptosis, but at the same time stimulate the expression of EGFR to interfere with the anti-apoptotic effect of the pharmaceutical composition of the present invention, indicating that the anti-tumor efficacy of the single pharmaceutical composition of the present invention is limited. In addition, according to pharmacological and functional analysis, the EGRF protein that promotes the anti-apoptotic expression of the pharmaceutical composition of the present invention was discovered and fully verified for the first time. Therefore, it is proposed to use the combined treatment mode of the pharmaceutical composition of the present invention and the anti-EGFR gefitinib drug to inhibit the expression of Cav-1 protein and anti-apoptotic EGRF protein, significantly enhance tumor ablation, further illustrate the superiority of the traditional Chinese medicine compound, and have strong clinical and social significance.

[0051] The above is only a preferred embodiment of the present invention, but the present invention should not be limited to the contents disclosed in the embodiment. Therefore, any equivalent or modification completed without departing from the spirit disclosed in the present invention shall fall within the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for treating esophageal cancer, characterized in that: The invention is prepared from the following medicines in parts by weight: 10-20 parts of processed arisaema, 20-40 parts of lithospermum officinale, 10-20 parts of codonopsis pilosula, 10-20 parts of schisandra chinensis, 6-10 parts of gecko, 10-20 parts of stewed terminalia chebula and 10-20 parts of citrus aurantium.

2. The Chinese medicine composition for treating esophageal cancer according to claim 1, characterized in that: The Chinese medicine composition for treating esophageal cancer is prepared from the following medicines in parts by weight: 15 parts of processed Arisaema, 30 parts of Lithospermum officinale, 15 parts of Codonopsis pilosula, 15 parts of Rhizoma Aconitum, 9 parts of Gekko, 15 parts of stewed Terminalia chebula and 15 parts of Prunus mume.

3. A method for preparing the Chinese medicine composition for treating esophageal cancer according to any one of claims 1 to 2, characterized in that: The following steps are involved: Take each drug according to the above weight ratio, add water 10 to 20 times the total weight of the drugs, soak for 20 to 60 minutes, then heat and boil for 30 minutes to 2 hours, then filter, freeze-dry the filtrate, collect the yellow powder and store it at 4 to 10°C to obtain the product.

4. A drug for treating esophageal cancer, characterized in that: The invention comprises the Chinese medicine composition according to any one of claims 1 to 2 and a pharmaceutically acceptable carrier.

5. The drug for treating esophageal cancer according to claim 4, characterized in that: The medicine for treating esophageal cancer is an oral preparation.

6. Use of the traditional Chinese medicine composition according to any one of claims 1 to 2 in the preparation of a drug for treating esophageal cancer.

7. The use according to claim 6, characterized in that: The traditional Chinese medicine composition is used in combination with an anti-tumor drug.

8. The use according to claim 7, characterized in that: The anti-tumor drug is selected from anti-EGFR drugs.

9. The use according to claim 8, characterized in that: The anti-EGFR drug is selected from any one or more of gefitinib, osimertinib, icotinib, erlotinib and afatinib.

10. The use according to any one of claims 7 to 9, characterized in that: The therapeutic effect of esophageal cancer is to inhibit tumor growth and prolong the patient's survival period.

Images